Arkolith/Insider Trading/ACRS/Form 4

Balthaser Kevin

Chief Financial OfficerAclaris Therapeutics, Inc. (ACRS) · full profile →Form 4 · filed Feb 3, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 1, 2026Tax withholding(F)5K$3.51$17K170K
Feb 1, 2026Option exercise(M)15K——175K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 1, 2026Option exercise(M)15K—$030K

Transaction Codes

F
Shares withheld for taxes
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001957554-26-000005) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML